Jim Cramer on Abbott: “Patience is a Virtue With ABT”

Abbott Laboratories (NYSE:ABT) is one of the stocks that Jim Cramer shared insights on. While discussing the stock, Cramer recommended patience, as he commented:

“Then one of my absolute favorite companies, medical device maker, Abbott Labs reports. And you know, I always like to tell you which companies tend to be misinterpreted in a negative way during the earnings season. Abbott’s a textbook example. It bothers me, but there are always sellers who claim to be disappointed. So, if you don’t own any Abbott, may I suggest that you wait to see the numbers, wait for the stock’s opening, wait for the sellers to appear. Patience is a virtue with ABT.”

An operating room with a doctor monitoring a patient’s vital signs during surgery with a medical device.

Abbott Laboratories (NYSE:ABT) develops and sells healthcare products, including pharmaceuticals, diagnostics, medical devices, and nutritional items. The company’s products address conditions in areas like cardiovascular health, diabetes, infectious diseases, and chronic pain management. During a May episode, Cramer mentioned the stock and said:

“Okay, their forward PE shows that there’s going to be a, pretty much of an earnings explosion. And I think a lot of that’s going to be coming from Libre, which is their diabetes, they have the best diabetes device. It’s cheaper than everybody’s.

By the way, I think pound for pound, it’s better than Dexcom, and Dexcom stock was up very big today. Also, remember, Robert Ford runs Abbott, and he runs it incredibly well. And I also think they’re going to settle these lawsuits or win the lawsuits that have really kept the lid on the stock, and that’s going to happen in 2025.”

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.